On Sept. 8, the American Medical Association (AMA) announced the release of the Current Procedural Terminology (CPT) 2024 code set.

The CPT Editorial Panel, an independent body convened by the AMA, consolidated more than 50 codes to streamline COVID-19 vaccine reporting. Approved provisional codes (91318-91322) are intended to identify monovalent vaccine products from Moderna and Pfizer for immunization against COVID-19, once approved by the U.S. Food and Drug Administration. A new vaccine administration code (90480) was also approved for reporting the administration of any COVID-19 vaccine for any patient, replacing all previously approved product-specific vaccine administration codes.

Other notable additions to the CPT code set include codes to report product-specific respiratory syncytial virus (RSV) immunizations. According to the AMA, the five new CPT codes (90380, 90381, 90683, 90679, and 90678) were created for better tracking, reporting, and analysis to support data-driven planning and allocation.

The new CPT code set was also revised to include consumer-friendly Spanish language descriptors and clarify the reporting of evaluation and management services.

These revisions will become operational on Jan. 1, 2024.